Articles On Orthocell (ASX:OCC)

Would you have invested in Amazon in the 90s, when it was a scrappy startup exploiting this new thing called the ‘world wide web’? Or would you invest once it had bedded down the book business and was getting into groceries? With hindsight...

During the quarter, the company continued its clinician advocacy program to expand the network of referring clinicians and product use in centres of excellence.

The announcement lands just before markets open, ‘the TGA has approved our device’; the buy orders begin to pile up and the pre-open share price begins to surge. But while a nod from Australia’s drug and device regulator, the Therapeutic Go...

The regenerative medicine company is focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries.

Australian regenerative medicine company Orthocell (ASX:OCC) has announced positive results from its guided bone regeneration study.

Regenerative medicine company Orthocell (ASX: OCC) has completed a US FDA regulatory study demonstrating successful bone growth using its proprietary CelGro technology and intends to leverage the results to improve its chances of a successf...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

Last week markets had their worst week since the global financial crisis (GFC) and the carnage, at least on the ASX, continued yesterday. A virus that began at a live meat market in Wuhan has now spread to over 80,000 people globally and th...

ShareCafeAll The Dope On Emerald Clinics’ Limp Debut Having been long on promises but short on deliverables, the ASX listed cannabis sector is taking an evolutionary step from growing the stuff to proving that pot is indeed the healing herb...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

Regenerative medicine company Orthocell (ASX:OCC) has announced it has been granted Canadian and Japan divisional patents for CelGro.

Regenerative medicine company Orthocell (ASX:OCC) has reported a Research and Development (R&D) Tax Incentive refund of $2,904,545 for the financial year 2018/2019.

The European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). That gives Alterity 10 years of market exclusivity in the European Union...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

Who said you have to be patient to net a hefty return on an investment? There are 10 ASX small caps that tripled (gained 200 per cent or more) in a day in 2019. Stockhead recaps the lucky companies and the reason for their show-stopping per...

Regenerative medicine company Orthocell (ASX:OCC) says it has received confirmation from the US FDA that the proposed CelGro nerve regeneration animal study protocol meets requirements to support the near term 510(k) submission....

Pharmaxis (ASX:PXS) has some big news from its German partner, but won’t yet say whether it’s good or bad. The company has been waiting on pharmaceutical major Boehringer Ingelheim to decide whether it wants to go ahead and further develop...

Small-cap biotech company Orthocell Ltd [ASX:OCC] has entered a trading halt today. A request that will give them time to announce a fresh capital raise. As it stands we are scant for details. The post Orthocell Pauses Trading in Hopes for...

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Regenerative medicine company Orthocell (ASX: OCC) has been granted a key patent for a 16-year period relating to a potential breakthrough CelGro collagen rope device to enhance the surgical repair of anterior cruciate ligament (ACL) injuri...

Orthocell (ASX:OCC) has found a new use for its CelGro tech – anterior cruciate ligament (ACL) injuries. The ACL is a major stabilising ligament in the knee. Once it is ruptured, it cannot be healed it must be replaced and recovery takes se...

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. In this episode Tim chats all things regenerative medicine with Paul Anderson, founder and CEO of Orthocell (ASX:...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

Special Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 guests attending the event last week. Hosted by industry entrepreneur Brian Leedman, the luncheon was established to raise awareness of, and bu...

On Stockhead today: gold is good, but which miners offer the best returns, how ASX pot stocks are maturing, Orthocell’s technology might have saved Superman and Clinuvel’s FDA approval caps off 4000% rise. But first:   The day ahead Today t...

On Wednesday, small cap ASX biotech Orthocell (ASX:OCC) reported that its collagen scaffold technology CelGro was restoring some function and movement to quadriplegic patients. It would have brought a smile to the face of Christopher Reeve,...

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions.  CelGro® is r...

Aussie biotech Orthocell Ltd [ASX:OCC] has seen a magnificent spike in their share price today, up a whopping 21.5% at time of writing. Results from clinical trials of their core regenerative medical solution CelGro, have led to such spikes...

Regenerative medicine company Orthocell (ASX: OCC) came out of a trading halt this morning with positive interim clinical results for CelGro, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic,...

Australian regenerative medicine company Orthocell (ASX:OCC) has announced positive interim clinical results for the use of its CelGro for enhancing repair of peripheral nerves.

On Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intriguing bargain barrel stocks, the five 2019 IPO stocks delivering triple returns and Dorado-3 oil flow gets Carnarvon on track. But first:   Th...

On Stockhead today: the three biggest opportunities for digital transformation in pharma, why it’s time to get excited about cobalt again, the top 10 stocks that doubled (and even tripled) in 24 hours and the stocks investors are shorting r...

In 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks, why they gained and where they are now.   10. AssetOwl (ASX: AO1) +225% (16 April) A fellow micro-cap gave AssetOwl a massive leg up back...

The WA investment community will turn its attention to healthcare next Thursday, when the annual Biotech Lunch takes place in Perth. Hosted by industry entrepreneur Brian Leedman, the luncheon will provide a forum for brokers and investors...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

Shares of regenerative medicine company Orthocell Ltd [ASX:OCC] have soared in today’s trading, currently up over 11% at time of writing. The biotech small-cap released the final results today of their CelGro clinical trial, which was succe...

Follow-up results from a CelGro tendon regeneration clinical trial conducted by Perth-based regenerative medicine company Orthocell (ASX: OCC) has confirmed all patients achieved a successful tendon repair with no need for revision surgerie...

04 Sep 2019 - Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per …

Shares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further positive results for its CelGro technology. Patients who completed the company’s CelGro tendon regeneration trial reported they had regaine...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Regenerative medicine company Orthocell (ASX:OCC) has announced a Japanese patent for CelGro collagen rope.

The collagen ropes enhance soft tissue repairs to areas such as anterior cruciate ligaments or ACLs.

The healthcare industry of Australia is a key contributor in developing the economy. The companies who are in this industry, have to update them with the new medicine for the treatment of the diseases. The healthcare space of Australia is p...

We’ve been pondering the next recession since the GFC. There have been warning signs, in 2011, 2015, 2016 and the last quarter of last year. But Wednesday’s ‘inverted yield curve’ was the most ominous sign of all, considering every time it...

The pharmaceutical market in Australia is defined as a knowledge-intensive, technology-driven industry that is well poised to contribute to the overall economic activity and particularly enhance social wellbeing. The S&P/ASX 200 Health...

Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe...

Orthocell (ASX: OCC) published yet another batch of trial results relating to CelGro which it says validates its claim that the technique can deliver higher quality nerve repair compared to existing methods. Earlier this morning, the regene...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...